News
06-03-2013, 06:10 AM
NanoString Technologies, Inc., a privately held provider of life science tools for translational research and molecular diagnostic products, today announced new results from the combined data analysis of the Austrian Breast & Colorectal Cancer Study Group 8 (ABCSG-8) and Arimidex, Tamoxifen, Alone or in Combination studies.
More... (http://www.news-medical.net/news/20130603/NanoStrings-Prosigna-Breast-Cancer-Assay-can-help-identify-node-positive-early-stage-breast-cancer.aspx)
More... (http://www.news-medical.net/news/20130603/NanoStrings-Prosigna-Breast-Cancer-Assay-can-help-identify-node-positive-early-stage-breast-cancer.aspx)